{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:23:53Z","timestamp":1783070633088,"version":"3.54.6"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.hlc.2018.10.002","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T10:17:04Z","timestamp":1539598624000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological Therapy for Ventricular Arrhythmias: A State-of-the Art Review"],"prefix":"10.1016","volume":"28","author":[{"given":"Karin K.M.","family":"Chia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Kanagaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hellestrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Whalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2018.10.002_bib0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/CIRCEP.109.893628","article-title":"Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy","volume":"2","author":"Patel","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJM199611283352207","article-title":"Adjunctive drug therapy of acute myocardial infarction\u2014evidence from clinical trials","volume":"335","author":"Hennekens","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.10.002_bib0015","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.3892\/etm.2016.3657","article-title":"A meta-analysis of the effects of \u03b2-adrenergic blockers in chronic heart failure","volume":"12","author":"Zhang","year":"2016","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.hlc.2018.10.002_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hrthm.2015.09.029","article-title":"Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with beta1-selective beta-blockers in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"13","author":"Leren","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.10.002_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jacep.2015.05.008","article-title":"Mexiletine prevents recurrent torsades de pointes in acquired long QT syndrome refractory to conventional measures","volume":"1","author":"Badri","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0035","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.82.4.1106","article-title":"Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials","volume":"82","author":"Coplen","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0040","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/CIRCEP.115.003109","article-title":"Management of brugada syndrome: thirty-three-year experience using electrophysiologically guided therapy with class 1a antiarrhythmic drugs","volume":"8","author":"Belhassen","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0045","first-page":"665","article-title":"J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge","volume":"19","author":"Antzelevitch","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.hlc.2018.10.002_bib0050","author":"Al-Khatib","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11886-017-0887-1","article-title":"Predictors and therapy of cardiomyopathy caused by frequent ventricular ectopy","volume":"19","author":"Dabbagh","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.hlc.2018.10.002_bib0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hrthm.2017.12.018","article-title":"Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy","volume":"15","author":"Hyman","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCEP.113.000805","article-title":"Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study","volume":"7","author":"Ling","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0070","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1053\/euhj.2000.2142","article-title":"Magnesium: an antiarrhythmic drug, but only against very specific arrhythmias","volume":"21","author":"Brugada","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2018.10.002_bib0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ehjcvp\/pvv047","article-title":"Drug therapy in cardiac arrest: a review of the literature","volume":"2","author":"Lundin","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hlc.2018.10.002_bib0080","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1056\/NEJM199909163411203","article-title":"Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation","volume":"341","author":"Kudenchuk","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.10.002_bib0085","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1514204","article-title":"Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest","volume":"374","author":"Kudenchuk","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.10.002_bib0090","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.1161\/CIR.0000000000000261","article-title":"Part 7: adult advanced cardiovascular life support: 2015 American heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care","volume":"132","author":"Link","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.hlc.2018.10.002_bib0100","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ahj.2005.07.019","article-title":"Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers","volume":"150","author":"Hreybe","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2018.10.002_bib0105","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2012.12.017","volume":"61","author":"Russo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/emermed-2013-202973","article-title":"Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review","volume":"32","author":"deSouza","year":"2015","journal-title":"Emerg Med J"},{"key":"10.1016\/j.hlc.2018.10.002_bib0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(94)91048-0","article-title":"Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia","volume":"344","author":"Ho","year":"1994","journal-title":"Lancet (London England)"},{"key":"10.1016\/j.hlc.2018.10.002_bib0120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1445-5994.2005.00896.x","article-title":"Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia","volume":"35","author":"Kovoor","year":"2005","journal-title":"Intern Med J"},{"key":"10.1016\/j.hlc.2018.10.002_bib0125","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehl478","article-title":"Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review","volume":"28","author":"Ferreira-Gonzalez","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2018.10.002_bib0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2018.10.002_bib0135","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/europace\/euu194","article-title":"EHRA\/HRS\/APHRS expert consensus on ventricular arrhythmias","volume":"16","author":"Pedersen","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.hlc.2018.10.002_bib0140","first-page":"e269","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0145","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.CIR.102.7.748","article-title":"Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH)","volume":"102","author":"Kuck","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11886-017-0924-0","article-title":"Ventricular tachycardia with ICD shocks: when to medicate and when to ablate","volume":"19","author":"AbdelWahab","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.hlc.2018.10.002_bib0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0735-1097(96)00423-8","article-title":"Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence","volume":"29","author":"Lee","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0160","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/europace\/euq073","article-title":"Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators","volume":"12","author":"Van Herendael","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.hlc.2018.10.002_bib0165","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/HCO.0b013e32835b59db","article-title":"Electrical storm: definitions, clinical importance, and treatment","volume":"28","author":"Gao","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.10.002_bib0175","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4330\/wjc.v9.i6.521","article-title":"Management of ventricular tachycardia storm in patients with structural heart disease","volume":"9","author":"Muser","year":"2017","journal-title":"World J Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.017944","article-title":"Treatment of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: an international task force consensus statement","volume":"132","author":"Corrado","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.CIR.86.1.29","article-title":"Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia","volume":"86","author":"Wichter","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0190","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hrthm.2016.12.010","article-title":"Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy","volume":"14","author":"Ermakov","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0195","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jacc.2009.04.052","article-title":"Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry","volume":"54","author":"Marcus","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0200","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2004.11.043","article-title":"Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy","volume":"45","author":"Adabag","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0205","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0002-9149(81)90604-4","article-title":"Prognostic significance of 24\u2009hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study","volume":"48","author":"Maron","year":"1981","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0210","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0215","first-page":"534","volume":"99","author":"O\u2019Mahony","year":"2013","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1016\/j.hlc.2018.10.002_bib0220","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.hrthm.2015.12.048","article-title":"Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy","volume":"13","author":"Maron","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0225","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2018.10.002_bib0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/01.CIR.103.1.89","article-title":"Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias","volume":"103","author":"Schwartz","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0235","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/01.CIR.101.6.616","article-title":"Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome","volume":"101","author":"Moss","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0240","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jama.292.11.1341","article-title":"Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers","volume":"292","author":"Priori","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2018.10.002_bib0245","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jacc.2012.07.046","article-title":"Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol","volume":"60","author":"Chockalingam","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0250","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.0000125523.14403.1E","article-title":"Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome","volume":"109","author":"Schwartz","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0255","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.hrthm.2013.07.021","article-title":"Executive summary: HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes","volume":"10","author":"Priori","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0260","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.hlc.2016.01.012","article-title":"Clinical challenges in catecholaminergic polymorphic ventricular tachycardia","volume":"25","author":"Imberti","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2018.10.002_bib0265","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1540-8167.2005.40516.x","article-title":"Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations","volume":"16","author":"Swan","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0270","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.hrthm.2007.05.017","article-title":"Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Rosso","year":"2007","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0275","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2018.10.002_bib0280","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hrthm.2015.09.027","article-title":"Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade","volume":"13","author":"Padfield","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hlc.2018.10.002_bib0285","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1540-8159.2012.03421.x","article-title":"Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia","volume":"35","author":"Hong","year":"2012","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hlc.2018.10.002_bib0290","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/CIRCULATIONAHA.115.015731","article-title":"Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation","volume":"131","author":"De Ferrari","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.10.002_bib0295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03085972","article-title":"Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally","volume":"15","author":"Jongman","year":"2007","journal-title":"Neth Heart J"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618319437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618319437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:01:04Z","timestamp":1761415264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950618319437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1443950618319437"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2018.10.002","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Therapy for Ventricular Arrhythmias: A State-of-the Art Review","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2018.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}